945 Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the U.S.: Exploring Trends Since 2001

Abstract

INTRODUCTION: The combined mortality from hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) is rising worldwide and expected to uptrend. We aimed to evaluate incidence trends of these two cancers over last 15 years in the US population. METHODS: Data was extracted from National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology and End Results (SEER) for the period 2001-2015. Age-adjusted incidence and annual percent change (APC) were calculated to examine trends based on type of LC, gender, and race. SEER Stat software was used to analyze this data. RESULTS: There were 334,617 cases of both types of cancers from 2001 to 2015, of which 89.2% had hepatocellular carcinoma. Total of 71.4% were males, 76% Caucasians, 14.2% African Americans and 9.8% were others. There was significant uptrend in the incidence rates of these cancers for period of 2001-2015 with APC 3.6 (CI: 3.2, 4.0) (Figure 1). The rise in incidence of ICC were higher than HCC with APC of 7.1 (CI: 6.1, 8.2), 3.2 (2.6, 3.8), respectively (Table 1). Males had higher increase in HCC with APC of 3.2 (CI: 2.6, 3.8), and females had higher risk for ICC with APC 7.6 (CI: 6.4, 88.) (Table 2). Caucasians had the highest APC of combined cancers 3.9 (3.5, 4.3). The APCs were trending up for HCC & ICC among all races except in other race, that showing APC was trending down -0.5 (CI: -1.0, -0.1). CONCLUSION: Our data reveal alarming rise in the incidence rates, for both HCC and ICC, separately and combined. Males and females differ in the rising trends of these cancers and all races appear to harbor rise in the cancer incidence. Identifying and treating risk factors are crucial to prevent this fatal disease.